Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. - Wikidata - awgldk - TriplyDB

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.

http://www.wikidata.org/entity/Q34436163

about

Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders Neuroplasticity in response to cognitive behavior therapy for social anxiety disorder.Emerging targets for antidepressant therapies The evidence-based pharmacotherapy of social anxiety disorder Neurokinin 1 receptor antagonism as a possible therapy for alcoholism Novel targets for antidepressant therapies Subpopulations of neurokinin 1 receptor-expressing neurons in the rat lateral amygdala display a differential pattern of innervation from distinct glutamatergic afferents The clinical implications of mouse models of enhanced anxiety.Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.Area-dependent time courses of brain activation during video-induced symptom provocation in social anxiety disorder.Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics.Pharmacotherapy for social anxiety disorder: a systematic review.Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues.A genetic determinant of the striatal dopamine response to alcohol in men Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.A pharmacokinetic PET study of NK₁ receptor occupancy.Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Involvement of substance P and the NK-1 receptor in human pathology.Increased neural habituation in the amygdala and orbitofrontal cortex in social anxiety disorder revealed by FMRI.The neurocircuitry of fear, stress, and anxiety disorders World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Translational and reverse translational research on the role of stress in drug craving and relapse.Neural response to eye contact and paroxetine treatment in generalized social anxiety disorder Diagnostic Prediction for Social Anxiety Disorder via Multivariate Pattern Analysis of the Regional Homogeneity Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder.Substance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation.NK1 receptor antagonists under investigation for the treatment of affective disorders.Corticolimbic brain reactivity to social signals of threat before and after sertraline treatment in generalized social phobia Emerging treatments for depression.The NK1 receptor antagonist L822429 reduces heroin reinforcement.Relationships among cognition, emotion, and motivation: implications for intervention and neuroplasticity in psychopathology.Emerging anxiolytics.Neuroimaging predictors of treatment response in anxiety disorders.Studying the brain-gut axis with pharmacological imaging.Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [11C]GR205171.Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ.

P2860

Q24633835-3BE7CA81-DBBD-4FF9-B1FE-91B5DBCCFC60 Q24658278-65DB0C80-763F-4E1B-9699-5AB80175F72A Q27009995-0BD3A2BA-5D9E-4042-9CD2-9A5F3CAC3759 Q27339489-C8E8BB2E-95C7-433B-8F78-E1E2A9FC2116 Q28247614-9242400F-5B79-4820-810D-C451213A7D6E Q28262456-2C881CA4-A50E-41EF-B6BD-AB53FDDDBEDF Q28268781-37255CE2-422A-4E6B-A7E2-B3B681F2A89F Q28648254-F83544EA-8DDC-4A12-AA97-0E0D18652565 Q30470225-C9230599-CE19-444F-B8DB-F160692C9C82 Q30474232-D0575B44-CA6D-4DD4-A3DC-A849E0CB532D Q30479172-28C92FE6-AA11-49D7-82CC-253974B836BE Q30580448-10859393-E6C7-41D6-B5FA-3FA9DA15E988 Q31114020-6E866290-B783-4B4C-8C67-BB401C26660D Q33319625-B40FE8FD-B5F4-4A3B-9BCF-EDB2A9DB4D75 Q33815691-2FDA0269-BA57-4D89-9B60-BC6A9E719FCE Q33940215-264EC784-4C8E-4A9A-84F1-43A9D356E37A Q34077390-A16F3F70-8818-4D4F-8616-E0DDB4CD8F7F Q34137084-31E2C1C8-2AE3-4D8C-9D97-75FDC62A3274 Q34157073-2AEB9016-D034-4528-BA93-B7B8B8A6A163 Q34223613-4254CA5B-E31E-405C-922E-63648AD405CC Q34275762-A1DB2C0B-A599-42DE-BB27-24E10F256660 Q34413850-3456D275-7780-4D1D-9401-D83AACD25904 Q34499908-F09C5B15-2615-42E8-93D0-5ABEE707EC89 Q34660882-0FF2CDDD-A6EE-4633-8DF3-32CDF45AA104 Q34865036-9E083DDA-2B22-457C-9C47-7345E7412BF7 Q35332832-084AE590-6B0E-4892-943C-71E8B190B160 Q35591557-68037450-4A7B-4A6D-BDA5-32D301A743AC Q35769021-09BE9AA4-B1A1-41A8-8AA1-5008674E615E Q36174067-8792E760-F56B-445E-B02B-9B1E4DDCDB0E Q36205025-ED3D07B5-10ED-4B23-B6D5-891007ABD67E Q36458364-193D6BF4-411D-49CD-A4C9-2A09950337A6 Q36569739-F99BB926-318F-48CC-8854-1BE82A18EFB8 Q36655168-4C38857E-4B59-461D-8096-91E84C2D211E Q36775223-F6FB33CD-FC46-4DDA-8CEA-89089A2FEA41 Q36917403-FF9A3254-3171-4F7A-A2CF-01884BDE63BA Q36989910-70E3025C-F9A9-4585-9452-6F0FE9518794 Q37112952-B15626FE-1515-4CBA-ABDA-D0BD6BEEF63C Q37280264-530AB69A-7413-4E41-95F3-9F89A6D40D64 Q37347599-B13D70AF-A523-4FC4-A299-105ACE94EB17 Q37461957-81F49C8D-2A35-4CC2-B837-9F8DCB3E8C82

P2860

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.

http://www.wikidata.org/entity/Q34436163

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@ast

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@en

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@nl

type

label

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@ast

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@en

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@nl

prefLabel

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@ast

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@en

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@nl

P1433

Q34436163-366DB842-9A90-455F-9391-0ADE7EC17985

P1476

Q34436163-8C44F759-63DC-44BF-AF30-D571F3E18FFD

P2093

Q34436163-13D97724-F4C5-436A-A660-E37E3F7C07DC

Q34436163-20F5FF32-C9FA-4D45-B717-A29BB02D03A4

Q34436163-257063B5-7653-4DFC-A378-34389017C066

Q34436163-2DD82692-AEEF-4311-91B3-BC0354C40C5C

Q34436163-2EEEDEAF-E548-4945-9E1D-2884754D1117

Q34436163-588DCE42-5D7D-402B-BC99-FD248516787A

Q34436163-8339ECE6-F202-4D87-AF59-A332A7DB7A93

Q34436163-8807919A-C1F8-4134-BE73-A7D838DE90CB

Q34436163-A18E5D0D-07BD-420E-A82D-85AAAFECED85

Q34436163-C87AA4D8-CA16-4FC3-9DBA-CC84014812B8

P304

Q34436163-519DD904-3592-4C12-9580-110D15A3BDF8

P31

Q34436163-DBE77209-D889-4196-8FBC-CF7B6E03087A

P356

Q34436163-AC2F8486-7325-4969-A574-58B6D851A832

P407

Q34436163-FE7C855C-3C46-4F7C-9DAB-40F2670646E1

P433

Q34436163-4059D3DB-D47D-4443-9770-F2DE555C30ED

P478

Q34436163-5F6CE39E-B47E-4987-84AB-7D047692214C

P50

Q34436163-0EDCEE0E-AF8B-41D1-88B8-FEA4798EF4FB

Q34436163-32BC1B4E-7843-4A40-9AB3-36A7B7D1A399

Q34436163-49BEA560-9DCB-4123-9716-507DFDA0DA78

Q34436163-B92E5BB5-A704-48BC-BC21-3D7E282D1171

P577

Q34436163-FDA89F47-1094-438F-8A21-8594ED176105

P5875

Q34436163-C7CD6793-EAB2-402F-A3EB-DE0A74623592

P698

Q34436163-EF846C41-0624-4753-9EF3-FE30290524BE

P921

Q34436163-1BFE3B16-2C67-41E3-BB7E-462EDD511471

Q34436163-8F43CC56-1BA8-47AD-8351-28BEA889FBF3

P356

J.BIOPSYCH.2005.03.029

P1433

Biological Psychiatry

P1476

Cerebral blood flow changes af ...... 05171, citalopram, or placebo.

@en

P2093

Asa Michelgård

http://www.w3.org/2001/XMLSchema#string

Emilio Merlo Pich

http://www.w3.org/2001/XMLSchema#string

Eva Jacobsson

http://www.w3.org/2001/XMLSchema#string

Karin Flyckt

http://www.w3.org/2001/XMLSchema#string

Kurt Wahlstedt

http://www.w3.org/2001/XMLSchema#string

Lars-Göran Nilsson

http://www.w3.org/2001/XMLSchema#string

Lieuwe Appel

http://www.w3.org/2001/XMLSchema#string

Magnus Grohp

http://www.w3.org/2001/XMLSchema#string

Massimo Bani

http://www.w3.org/2001/XMLSchema#string

Mats Bergström

http://www.w3.org/2001/XMLSchema#string

P304

132-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BIOPSYCH.2005.03.029

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Bengt Långström

Mats Fredrikson

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7706165

http://www.w3.org/2001/XMLSchema#string

P698

16038684

http://www.w3.org/2001/XMLSchema#string

P921

cerebral blood flow